Výsledky vyhledávání - "Timothy Luger"

Data from 5-Azacytidine Transiently Restores Dysregulated Erythroid Differentiation Gene Expression in TET2-Deficient Erythroleukemia Cells

Autor: Rafael Bejar, Anjana Rao, Yun Huang, Kun Zhang, Dinh Diep, Tiffany Tanaka, Laura Williamson, Minjung Lee, Emily C. Wheeler, Edahí González-Avalos, Chan-Wang Jerry Lio, Soo Park, Timothy Luger, Brian M. Reilly

DNA methyltransferase inhibitors (DNMTI) like 5-Azacytidine (5-Aza) are the only disease-modifying drugs approved for the treatment of higher-risk myelodysplastic syndromes (MDS), however less than 50% of patients respond, and there are no predictors

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15751a727a4cd1f9bf11ada4fc5cc766
https://doi.org/10.1158/1541-7786.c.6544947.v1

Zobrazit plný text záznamu

Figure S4: Expression of key erythroid marker genes. from 5-Azacytidine Transiently Restores Dysregulated Erythroid Differentiation Gene Expression in TET2-Deficient Erythroleukemia Cells

A) Expression of hemoglobin genes which increase in terminally differentiated erythroid cells. B) Expression of key erythrocyte marker genes. TPM=Transcripts per kilobase million; a gene expression measure for RNAseq that normalizes for gene-length a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::623466af5b0b36d4e69432ea7848fc64
https://doi.org/10.1158/1541-7786.22525878

Zobrazit plný text záznamu

Figure S2: Optimizing 5-Aza dosage regimen in wild-type TF1. from 5-Azacytidine Transiently Restores Dysregulated Erythroid Differentiation Gene Expression in TET2-Deficient Erythroleukemia Cells

A) Dose-response curve of wild-type TF1 cell viability for three different lengths of 5-Aza treatments (1 dose per day for a total length of treatment between 1 and 3 days). Points represent replicates per condition, shaded region corresponds to 95%

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00da746ccd74bf3f24f9df60068c0885
https://doi.org/10.1158/1541-7786.22525887.v1

Zobrazit plný text záznamu

Figure S1: L-ascorbic acid (L-AA) exposure enhances 5hmC accumulation to a greater extent in TET2-WT TF1 cells. from 5-Azacytidine Transiently Restores Dysregulated Erythroid Differentiation Gene Expression in TET2-Deficient Erythroleukemia Cells

Cells were treated with 100uM L-AA or vehicle 24hrs before DNA isolation. A) 5hmC dot blot for L-AA treated or untreated Cells. B) Standard curve of 5hmC densitometric signal vs. pmol (calculated from 5hmC standard with known 5hmC amount). C) Quantif

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11adce67c9c056e6c144befbed6938cb
https://doi.org/10.1158/1541-7786.22525890.v1

Zobrazit plný text záznamu

Figure S3: Potential clustering solutions for defining groups of dynamic methylation clusters. from 5-Azacytidine Transiently Restores Dysregulated Erythroid Differentiation Gene Expression in TET2-Deficient Erythroleukemia Cells

Line plots in grid: each colored line represents a single CpG locus over time after 5-Aza treatment. Black line indicates mean value for that cluster group. Dotted black line indicates mean +/- 1 standard deviation. From left to right: clustering sol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbbb7b132329df7d98bca39726bf1946
https://doi.org/10.1158/1541-7786.22525881

Zobrazit plný text záznamu

Abstract 1435: Clonal hematopoiesis profiles in breast cancer survivors using error-corrected sequencing

Autor: Soo J. Park, Zhan (Jack) Rong, Laura Williamson, Timothy Luger, Emily Johnson, Sheri Hartman, Christopher J. Gibson, R. Coleman Lindsley, Dorothy D. Sears, Rafael Bejar

Publikováno v: Cancer Research. 82:1435-1435

Background: Cytotoxic therapy increases the risk of clonal hematopoiesis (CH) defined by somatic mutations of cancer-associated genes in blood stem cells. CH is associated with secondary blood cancers and other adverse health events, although the min

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9b1708296abe5324add32a1299fde803
https://doi.org/10.1158/1538-7445.am2022-1435

Zobrazit plný text záznamu

5-Azacytidine Transiently Restores Dysregulated Erythroid Differentiation Gene Expression in TET2-Deficient Erythroleukemia Cells

Autor: Anjana Rao, Rafael Bejar, Kun Zhang, Soo J. Park, Dinh Diep, Emily C. Wheeler, Timothy Luger, Brian M. Reilly, Minjung Lee, Tiffany N. Tanaka, Laura Williamson, Edahí González-Avalos, Yun Huang, Chan Wang Jerry Lio

Publikováno v: Molecular cancer research : MCR, vol 19, iss 3
Mol Cancer Res

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f07c8c549ef68106ee0e45d098d743a
https://escholarship.org/uc/item/5w08d0bk

Zobrazit plný text záznamu

Phenotypic and Proliferative Analysis of T Cell and Monocyte Populations in Patients with Intermediate/High/Very High-Risk MDS Compared to Age-Matched Healthy Donors

Autor: Xinlian Zhang, Hannah Fields, Thomas A. Lane, Alison Tarke, Rafael Bejar, Randy Guo-Shi Tsai, Colin McCarthy, Timothy Luger, Tiffany N. Tanaka, Valentina Ferrari, Antonella Vitiello, Ruifeng Chen

Publikováno v: Blood. 136:25-26

Background: Myelodysplastic syndromes (MDS) have been associated with alterations in the bone marrow microenvironment and include abnormal innate and adaptive immune responses. The extent to which these changes contribute to the pathogenesis of MDS i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::280d278a5e1c7563408b1ede3c6a0fdc
https://doi.org/10.1182/blood-2020-142038

Zobrazit plný text záznamu

DNA Methylation Analysis before and during Treatment with Azacitidine Plus Pevonedistat or Azacitidine Alone in Patients with MDS, CMML, and AML Previously Untreated with Hypomethylating Agents

Autor: Timothy Luger, Brian M. Reilly, Soo J. Park, Dan Zhao, Rafael Bejar, Robert J. Fram, Ajeeta B Dash

Publikováno v: Blood. 136:29-30

Background: Clinical responses to hypomethylating agents (HMA) occur in the minority of patients with myelodysplastic syndromes (MDS) and related disorders and require months of treatment. Robust biomarkers of HMA response would have great clinical u

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::13c93e99a230883639e674f3e3615849
https://doi.org/10.1182/blood-2020-134484

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání